Strategies to target long-lived plasma cells for treating hemophilia A inhibitors
CL Liu, MJ Lyle, SC Shin, CH Miao - Cellular immunology, 2016 - Elsevier
Long-lived plasma cells (LLPCs) can persistently produce anti-factor VIII (FVIII) antibodies
which disrupt therapeutic effect of FVIII in hemophilia A patients with inhibitors. The
migration of plasma cells to BM where they become LLPCs is largely controlled by an
interaction between the chemokine ligand CXCL12 and its receptor CXCR4. AMD3100
combined with G-CSF inhibit their interactions, thus facilitating the mobilization of CD34+
cells and blocking the homing of LLPCs. These reagents were combined with anti-CD20 to …
which disrupt therapeutic effect of FVIII in hemophilia A patients with inhibitors. The
migration of plasma cells to BM where they become LLPCs is largely controlled by an
interaction between the chemokine ligand CXCL12 and its receptor CXCR4. AMD3100
combined with G-CSF inhibit their interactions, thus facilitating the mobilization of CD34+
cells and blocking the homing of LLPCs. These reagents were combined with anti-CD20 to …